Vascepa is a prescription drug used to treat high levels of triglycerides in the blood. The drug is manufactured by Amarin Corporation, and it has been approved for use in Europe under the name Vazkepa [3].

According to the sources provided, the cost of Vascepa in Europe is not explicitly stated. However, we can infer that the drug will be priced similarly to other prescription drugs used to treat high levels of triglycerides.

Amarin Corporation recently launched Vazkepa in Europe, and the drug is expected to become a blockbuster heart drug slowly [2]. This suggests that the drug may be priced at a premium compared to other prescription drugs used to treat high levels of triglycerides.

DrugPatentWatch, a database of pharmaceutical patents, lists several patents related to Vascepa that will expire in the coming years [1]. Once these patents expire, it is possible that generic versions of the drug will become available, which could reduce the cost of the drug.

In summary, the cost of Vascepa in Europe is not explicitly stated in the sources provided. However, we can infer that the drug will be priced similarly to other prescription drugs used to treat high levels of triglycerides, and it may be priced at a premium due to its expected success as a heart drug. Once patents related to Vascepa expire, it is possible that generic versions of the drug will become available, which could reduce the cost.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/marketing/amarin-launches-vascepa-all-important-europe-as-blockbuster-to-be-heart-drug-slowly
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa